Saskatoon, Saskatchewan, Canada
November 9, 2007
Philom Bios Inc. (Philom
Bios) announced today that it has filed its Directors Circular
with securities regulators in Canada and has mailed it to Philom
Bios shareholders.
The Directors Circular contains a unanimous recommendation from
the Board of Directors of Philom Bios to accept the all-cash
offer filed by Novozymes
Biologicals Holding A/S (“Novozymes”), a wholly-owned
subsidiary of Novozymes A/S, to acquire all of the issued and
outstanding shares of Philom Bios as contemplated in the
take-over bid. The Board of Directors unanimously recommends
that Philom Bios shareholders tender their common shares to
Novozymes offer before December 10, 2007.
The documents pertaining to the take-over bid have been mailed
to Philom Bios shareholders and can be obtained free of charge
through the System for Electronic Documents Analysis and
Retrieval (SEDAR) at www.sedar.com and at
www.philombios.com/investors.html.
Philom Bios is a world leading inoculant company with over 70
employees across North America in research, manufacturing,
marketing and management and in its joint-venture operations in
Australia. Headquartered in Saskatoon, SK, Philom Bios is a
Canadian public company serving the needs of farmers with
high-value inoculants. Philom Bios has an over 25 year
commitment to farmers through a dynamic partnership with
distributors and leading retailers. Read more at
www.philombios.com
Novozymes is the world leader in bio-innovation. Together with
customers across a broad array of industries, Novozymes creates
tomorrow’s industrial bio-solutions, improving its customers'
business and the use of our planet's resources. With over 700
products used in 130 countries, Novozymes’ bio-innovations
improve industrial performance and safeguard the world’s
resources by offering superior and sustainable solutions for
tomorrow’s ever-changing marketplace. Read more at
www.novozymes.com. |
|
